Eli Lilly’s ‘triple-G’ drug shows strong potency as Azalea advances in vivo CAR-T therapy in mice

Eli Lilly's 'triple-G' drug has demonstrated potent efficacy, fueling optimism in cancer treatment advancements. Concurrently, Azalea Therapeutics, emerging from Jennifer Doudna's lab, achieved promising tumor clearance in mice using in vivo CAR-T therapy that edits T cells directly inside the body. These parallel breakthroughs highlight evolving approaches to immunotherapy, with clinical development and human trials anticipated next.